Cencora vs McKesson
McKesson holds the stronger position because it won the OptumRx contract away from Cardinal Health in 2025 and posted higher FY2025 revenue than Cencora, while Cencora faces heavier direct contract-switching pressure within the Big Three drug distributors.
Cencora
Cencora moves prescription drugs from manufacturers to pharmacies and hospitals across the US.
McKesson
Drug wholesaler moving roughly a third of North America's prescription medicines
Dimension by dimension
| Dimension | Cencora | McKesson |
|---|---|---|
| staying power of the core product | Cencora is also rated hard to displace, running the same kind of drug distribution business at large scale. | McKesson is rated hard to displace, moving about a third of all U.S. pharma products with no visible customer loss. |
| exposure to AI | AI is unlikely to absorb Cencora's core distribution function either. | AI is unlikely to absorb McKesson's core distribution function. |
| how easily a giant copies them | Cencora's position is marked as blocked to giant replication as well. | McKesson's position is marked as blocked to giant replication. |
| pressure from rivals | Cencora faces contract switching within the Big Three, and McKesson specifically took the OptumRx contract away from Cardinal Health in 2025. | No meaningful customer loss shows up in the evidence for McKesson. |
| financial footing | Cencora posted $321.3 billion in FY2025 revenue, $16.00 adjusted diluted EPS, and $85.9 billion in Q1 FY2026 revenue. | McKesson posted $359.05 billion in FY2025 revenue, 12% year over year growth in FY2026, and $5.4 billion in FY2026 free cash flow. |
Questions people ask
- Will AI disrupt McKesson or Cencora's business
- Neither company's core business is expected to be absorbed by AI. Both McKesson and Cencora are rated unlikely on this measure, since physically distributing prescription drugs is not something AI replaces.
- What is the financial difference between McKesson and Cencora
- McKesson reported $359.05 billion in FY2025 revenue with 12% growth and $5.4 billion in free cash flow in FY2026. Cencora reported $321.3 billion in FY2025 revenue and $16.00 in adjusted diluted EPS, with Q1 FY2026 revenue of $85.9 billion.
- Who faces more competitive pressure, McKesson or Cencora
- Cencora faces more visible pressure since contracts can shift within the Big Three distributors, and McKesson specifically took the OptumRx contract from Cardinal Health in 2025. McKesson shows no meaningful customer loss in the evidence provided.
Other comparisons with these companies